Australia's TGA updates licensing and certification guidance

4 August 2017

A package of new and updated guidance on licensing and certification processes for manufacturers of medicines and biologicals in Australia, has been developed in consultation with the Therapeutic Goods Administration (TGA) Industry Working Group on GMP (TIWGG), to better support manufacturers and sponsors and provide additional clarity for applicants.

The new guidance does not introduce changes to the current process or requirements, existing processes have merely been documented with additional clarity.

The updated package of guidance was published in August 2017 and is now available on the TGA website, on the Manufacturing Therapeutic Goods pages.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK